Literature DB >> 7907637

CD4+ T cell-dependent acquired state of immunity that protects the brain against Cryptococcus neoformans.

J O Hill1, K M Aguirre.   

Abstract

In immunodeficient hosts, a failure in defense mechanisms allows Cryptococcus neoformans to establish foci of infection in the brain. Immune and nonspecific responses in the primary site of infection in the lung have been described, but those extrapulmonary defense mechanisms that can be mobilized against the yeast have received little attention. This paper describes a response expressed against yeast in the brain of immunocompetent hosts, a response that is weakened in hosts deficient in CD4+ T cells. When a small number of yeast gain access to the vasculature, for example through an i.v. injection, about 0.1% establish themselves in the brain. Normal mice but not SCID mice have the capacity to suppress the multiplication of these yeast cells. The host response is accelerated in mice that are recovering from a primary lung infection, resulting in long term survival without antibiotic chemotherapy. This response is ablated by anti-CD4 mAb treatment and CD4+ cells obtained from infected primed donors are needed to confer immunity on SCID recipients. The critical target for the anti-Cryptococcus immune response are yeast in the brain cortex. However, rather than preventing the colonization of the brain by blood-borne yeast, immunity apparently serves to restrict the growth of yeast in a small number of established foci.

Entities:  

Mesh:

Year:  1994        PMID: 7907637

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Requirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice.

Authors:  K L Buchanan; H A Doyle
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 2.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

3.  Effect of a CD4-depleting antibody on the development of Cryptococcus neoformans-induced allergic bronchopulmonary mycosis in mice.

Authors:  Shikha Arora; Roderick A McDonald; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Effect of cytokines on anticryptococcal activity of human microglial cells.

Authors:  M M Lipovsky; A E Juliana; G Gekker; S Hu; A I Hoepelman; P K Peterson
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

Review 5.  Role of microglia in fungal infections of the central nervous system.

Authors:  George W Koutsouras; Raddy L Ramos; Luis R Martinez
Journal:  Virulence       Date:  2016-11-18       Impact factor: 5.882

Review 6.  The intracellular life of Cryptococcus neoformans.

Authors:  Carolina Coelho; Anamelia L Bocca; Arturo Casadevall
Journal:  Annu Rev Pathol       Date:  2013-09-16       Impact factor: 23.472

7.  Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.

Authors:  D O Beenhouwer; S Shapiro; M Feldmesser; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

8.  Decreased resistance to primary intravenous Cryptococcus neoformans infection in aged mice despite adequate resistance to intravenous rechallenge.

Authors:  K M Aguirre; G W Gibson; L L Johnson
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Induction of T helper type 1 responses by a polysaccharide deacetylase from Cryptococcus neoformans.

Authors:  Carmelo Biondo; Concetta Beninati; Mauro Bombaci; Luciano Messina; Giuseppe Mancuso; Angelina Midiri; Roberta Galbo; Giuseppe Teti
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Biomolecular events involved in anticryptococcal resistance in the brain.

Authors:  E Blasi; R Barluzzi; R Mazzolla; L Pitzurra; M Puliti; S Saleppico; F Bistoni
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.